2023
Antibody-mediated antigen loss switches augmented immunity to antibody-mediated immunosuppression
Jajosky R, Patel K, Allen J, Zerra P, Chonat S, Ayona D, Maier C, Morais D, Wu S, Luckey C, Eisenbarth S, Roback J, Fasano R, Josephson C, Manis J, Chai L, Hendrickson J, Hudson K, Arthur C, Stowell S. Antibody-mediated antigen loss switches augmented immunity to antibody-mediated immunosuppression. Blood 2023, 142: 1082-1098. PMID: 37363865, PMCID: PMC10541552, DOI: 10.1182/blood.2022018591.Peer-Reviewed Original ResearchMeSH KeywordsAntibodiesErythroblastosis, FetalErythrocytesFemaleHumansImmune ToleranceImmunosuppression TherapyInfant, NewbornIsoantibodiesIsoantigensRho(D) Immune GlobulinConceptsAntibody-mediated immunosuppressionRBC alloantigensImmune responseFetal red blood cell antigensTarget antigenRed blood cell antigensRh immune globulinMaternal immune responseBlood cell antigensInclusion of antibodiesRBC removalAnti-RhD antibodiesAbility of antibodiesImmune globulinAntibody responseHemolytic diseaseRBC clearanceCell antigensFetal RBCsAntibody characteristicsAlloantigensSimilar interventionsAntibodiesAntigenPolyclonal antibody preparation
2022
International guidelines regarding the role of IVIG in the management of Rh‐ and ABO‐mediated haemolytic disease of the newborn
Lieberman L, Lopriore E, Baker JM, Bercovitz RS, Christensen RD, Crighton G, Delaney M, Goel R, Hendrickson JE, Keir A, Landry D, La Rocca U, Lemyre B, Maier RF, Muniz‐Diaz E, Nahirniak S, New HV, Pavenski K, dos Santos M, Ramsey G, Shehata N, Guidelines F. International guidelines regarding the role of IVIG in the management of Rh‐ and ABO‐mediated haemolytic disease of the newborn. British Journal Of Haematology 2022, 198: 183-195. PMID: 35415922, PMCID: PMC9324942, DOI: 10.1111/bjh.18170.Peer-Reviewed Original ResearchMeSH KeywordsBlood Group IncompatibilityErythroblastosis, FetalExchange Transfusion, Whole BloodFemaleHumansImmunoglobulins, IntravenousInfant, NewbornPhototherapyConceptsRole of IVIGIntravenous immunoglobulinExchange transfusionHaemolytic diseaseSafety of IVIGRed blood cell transfusionBlood cell transfusionDuration of hospitalizationSeverity of anemiaEvidence-based recommendationsHigh-quality studiesCell transfusionPrompt treatmentBilirubin levelsSignificant morbidityAlternative therapiesIntensive phototherapyNeurocognitive outcomesManagement of RhInternational guidelinesTransfusionNewbornsDiseasePhototherapyInternational panel
2020
Poly(I:C) causes failure of immunoprophylaxis to red blood cells expressing the KEL glycoprotein in mice
Escamilla-Rivera V, Liu J, Gibb DR, Santhanakrishnan M, Liu D, Forsmo JE, Eisenbarth S, Foxman EF, Stowell SR, Luckey CJ, Zimring JC, Hudson KE, Hendrickson J. Poly(I:C) causes failure of immunoprophylaxis to red blood cells expressing the KEL glycoprotein in mice. Blood 2020, 135: 1983-1993. PMID: 32266378, PMCID: PMC7256361, DOI: 10.1182/blood.2020005018.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCD4-Positive T-LymphocytesCytokinesDisease Models, AnimalErythroblastosis, FetalErythrocyte TransfusionErythrocytesFemaleHumansImmunization, PassiveInterferon Type IIsoantigensKell Blood-Group SystemMembrane GlycoproteinsMetalloendopeptidasesMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicPhagocytosisPoly I-CPregnancyConceptsRed blood cellsSerum monocyte chemoattractant protein-1Monocyte chemoattractant protein-1Blood cellsHuman KEL glycoproteinPolyinosinic-polycytidilic acidTransfused red blood cellsType 1 IFNType I IFN receptorChemoattractant protein-1Type 1 interferonI IFN receptorMurine red blood cellsRecipient CD4Recipient inflammationIFN administrationSerum cytokinesInflammatory monocytesRecipient treatmentInterleukin-6Hemolytic diseaseT cellsMurine modelAlloimmunizationKnockout mice